Upside case
Bull case
$320+108.6%
VEEV would need investors to value it at roughly 35x earnings — about 18x more generous than today's 17x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Analysis OverviewBuyUpdated Jun 18, 2026
Veeva Systems Inc. (VEEV) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
43
analysts
29 bullish · 1 bearish · 43 covering VEEV
Strong Buy
0
Buy
29
Hold
13
Sell
1
Strong Sell
0
Consensus Target
$235
+53.5% vs today
Scenario Range
$153 – $320
Model bear to bull value window
Coverage
43
Published analyst ratings
Valuation Context
16.9x
Forward P/E · Market cap $24.9B
VEEV price targets
Three scenarios for where VEEV stock could go
Current
~$153
Confidence
60 / 100
Updated
Jun 18, 2026
Where we are now
Current · $153
Bear
$153
Base
$243
Bull
$320
Market caseClosest to today
Base case
$243+58.3%
At 27x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
Stress case
Bear case
$153-0.3%
If investor confidence fades or macro conditions deteriorate, a 0x multiple contraction could push VEEV down roughly 0% from where it trades now.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Veeva Systems Inc.
VEEV · NYSEHealthcareMedical - Healthcare Information ServicesJanuary year-end
Veeva Systems provides cloud-based software specifically designed for the life sciences industry, including pharmaceutical and biotech companies. It generates revenue primarily through subscription fees for its Veeva Commercial Cloud and Veeva Vault platforms — which together account for the vast majority of its income — supplemented by professional services for implementation and support. The company's key advantage is its deep industry specialization and regulatory compliance expertise, creating a high-switching-cost moat within the tightly regulated life sciences sector.
Market Cap
$24.9B
Revenue TTM
$3.3B
Net Income TTM
$942M
Net Margin
28.4%
VEEV Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
92%Exceptional
12 quarters tracked
Revenue Beat Rate
100%Exceptional
vs consensus estimates
Avg EPS Surprise
+4.3%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q4 2025
Q1 2026
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 3 of 4Q4 2025
EPS
$2.04/$1.95
Revenue
$811M/$793M
Q1 2026
EPS
$2.06/$1.94
Revenue
$836M/$811M
Q1 2026
EPS
$1.49/$1.94
Revenue
$836M/$811M
Q2 2026
EPS
$2.24/$2.14
Revenue
$883M/$858M
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q4 2025 | $2.04/$1.95 | +4.6% | $811M/$793M | +2.3% |
| Q1 2026 | $2.06/$1.94 | +6.2% | $836M/$811M | +3.1% |
| Q1 2026 | $1.49/$1.94 | -23.2% | $836M/$811M | +3.1% |
| Q2 2026 | $2.24/$2.14 | +4.7% | $883M/$858M | +2.9% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$3.8B
+13.5% YoY
FY2
$4.2B
+11.1% YoY
EPS Outlook
FY1
$7.59
+33.8% YoY
FY2
$8.27
+9.0% YoY
Trailing FCF (TTM)$518M
FCF Margin: 15.6%
Next Earnings
—
Expected EPS
—
Expected Revenue
—
VEEV beat EPS estimates in 3 of 4 tracked quarters. A strong delivery record supports forward estimate credibility.
VEEV Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2026
Total disclosed revenue $1.4B
Product Mix
Latest annual revenue by segment or product family
Subscription Services Veeva Commercial Cloud
86.9%
+13.8% YoY
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
North America
60.9%
+17.4% YoY
Tap, hover, or focus a slice to inspect segment detail.
Subscription Services Veeva Commercial Cloud is the largest disclosed segment at 86.9% of FY 2026 revenue, up 13.8% YoY.
North America is the largest reported region at 60.9%, up 17.4% YoY.
VEEV Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Expensive versus peers
Fair value est. $122 — implies -20.6% from today's price.
Premium to Fair Value
20.6%
above fair value
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
VEEV
28.2x
vs
S&P 500
24.4x
+15% premium
vs Healthcare Trailing P/E
VEEV
28.2x
vs
Healthcare
22.1x
+27% premium
vs VEEV 5Y Avg P/E
Today
28.2x
vs
5Y Average
60.5x
53% discount
Forward PE
16.9x
S&P 500
18.8x
-10%
Healthcare
18.3x
-8%
5Y Avg
—
—
Trailing PE
28.2x
S&P 500
24.4x
+15%
Healthcare
22.1x
+27%
5Y Avg
60.5x
-53%
PEG Ratio
1.55x
S&P 500
1.66x
-7%
Healthcare
1.59x
-3%
5Y Avg
—
—
EV/EBITDA
19.7x
S&P 500
15.2x
+30%
Healthcare
14.2x
+39%
5Y Avg
55.2x
-64%
Price/FCF
18.0x
S&P 500
20.7x
-13%
Healthcare
18.5x
-3%
5Y Avg
37.2x
-52%
Price/Sales
7.8x
S&P 500
3.1x
+152%
Healthcare
2.6x
+196%
5Y Avg
14.5x
-46%
Dividend Yield
—
S&P 500
1.91%
—
Healthcare
1.50%
—
5Y Avg
—
—
| Metric | VEEV | S&P 500 | Healthcare | 5Y Avg VEEV |
|---|---|---|---|---|
| Forward PE | 16.9x | 18.8x-10% | 18.3x | — |
| Trailing PE | 28.2x | 24.4x+15% | 22.1x+27% | 60.5x-53% |
| PEG Ratio | 1.55x | 1.66x | 1.59x | — |
| EV/EBITDA | 19.7x | 15.2x+30% | 14.2x+39% | 55.2x-64% |
| Price/FCF | 18.0x | 20.7x-13% | 18.5x | 37.2x-52% |
| Price/Sales | 7.8x | 3.1x+152% | 2.6x+196% | 14.5x-46% |
| Dividend Yield | — | 1.91% | 1.50% | — |
VEEV trades above S&P 500 benchmarks on 3 of 6 measured multiples — is elevated on some multiples, but competitive on others — a mixed valuation picture.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolVEEV Financial Health
Verdict
Strong
VEEV generates $518M in free cash flow at a 15.6% margin — 12.9% ROIC signals a durable competitive advantage.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$3.3B
Revenue Growth
TTM vs prior year
+16.2%
Gross Margin
Gross profit as a share of revenue
75.0%
Operating Margin
Operating income divided by revenue
28.8%
Net Margin
Net income divided by revenue
28.4%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$5.67
Free Cash Flow (TTM)
Cash generation after capex
$518M
FCF Margin
FCF as share of revenue — the primary cash quality signal
15.6%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
12.9%
ROA
Return on assets, trailing twelve months
11.0%
Cash & Equivalents
Liquid assets on the balance sheet
$1.4B
Net Cash
Cash exceeds total debt — no net leverage
$1.3B
Debt Serviceability
Net debt as a multiple of annual free cash flow
Net cash ✓
ROE
Return on equity, trailing twelve months
13.4%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
0.7%
Dividend
—
Buyback
0.7%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$170M
Dividend / Share
Annualized trailing dividend per share
—
Payout Ratio
Share of earnings distributed as dividends
—
Shares Outstanding
Declining as buybacks retire shares
162M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageVEEV Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated June 18, 2026
High Risk
Revenue growth slowdown
Revenue growth slowed to 16% year over year in fiscal year 2026, potentially indicating market saturation or competitive pressures.
High Risk
Customer concentration risk
Veeva serves essentially every major pharmaceutical and biotech company, making revenue highly dependent on a concentrated customer base.
Medium
Guidance uncertainty
Forward-looking statements and guidance are inherently difficult to estimate accurately, creating potential for earnings volatility.
Medium
Numerous disclosed risks
The company disclosed 43 risk factors in its most recent earnings report, indicating multiple potential challenges across operations.
Lower
Valuation concerns
Despite strong fundamentals, the stock price decline may reflect valuation concerns or market skepticism about future growth.
Lower
Industry specialization risk
Being entirely focused on the life sciences industry makes Veeva vulnerable to sector-specific downturns or regulatory changes.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why VEEV Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated June 18, 2026
Industry cloud leadership
Veeva delivers a comprehensive industry cloud for life sciences, combining software, AI, data, and consulting services, serving over 1,500 customers.
AI-driven productivity tools
Veeva's AI Agents for Vault CRM and PromoMats enhance productivity across clinical, regulatory, safety, quality, medical, and commercial operations.
High-margin recurring revenue
The company benefits from high-margin recurring revenue streams, strong cash flows, and a robust $5 billion net cash position.
Strong analyst consensus
As of 2026, 29 out of 43 analysts rate VEEV as Buy or Strong Buy, with a consensus price target implying 44.1% upside potential.
Innovation and product excellence
Veeva is committed to continuous innovation and product excellence, driving customer success in the life sciences industry.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
VEEV Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$153.30
52W Range Position
3%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$148.05
+3.5% from the low
52-Week High
$310.50
-50.6% from the high
1 Month
-6.44%
3 Month
-16.70%
YTD
-30.2%
1 Year
-45.5%
3Y CAGR
-8.8%
5Y CAGR
-13.0%
10Y CAGR
+16.2%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
VEEV vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
16.9x
vs 14.3x median
+18% above peer median
Revenue Growth
+13.5%
vs +11.2% median
+21% above peer median
Net Margin
28.4%
vs 18.7% median
+51% above peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
VEE VEEV Veeva Systems Inc. | $24.9B | 16.9x | +13.5% | 28.4% | Buy | +53.5% |
CRM CRM Salesforce, Inc. | $124.3B | 12.9x | +9.2% | 18.7% | Buy | +75.1% |
DOC DOCS Doximity, Inc. | $3.8B | 14.3x | +11.2% | 30.4% | Hold | +44.0% |
MED MEDP Medpace Holdings, Inc. | $13.1B | 27.1x | +9.8% | 17.2% | Hold | +8.4% |
HUB HUBS HubSpot, Inc. | $9.0B | 13.4x | +14.9% | 3.0% | Buy | +62.0% |
DSG DSGX The Descartes Systems Group Inc. | $5.8B | 36.1x | +11.5% | 23.4% | Buy | +46.5% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
VEEV Dividend and Capital Return
VEEV returns 0.7% annually — null% through dividends and 0.7% through buybacks.
Dividend UnknownFCF Unknown
Total Shareholder Yield
0.7%
Dividend + buyback return per year
Buyback Yield
0.7%
Dividend Yield
—
Payout Ratio
—
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$0.00
Growth Streak
Consecutive years of dividend increases
0Y
3Y Div CAGR
—
5Y Div CAGR
—
Ex-Dividend Date
—
Payment Cadence
—
0 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$170M
Estimated Shares Retired
1M
Approx. Share Reduction
0.7%
Shares Outstanding
Current diluted share count from the screening snapshot
162M
At 0.7%/year, buybacks mechanically lift EPS even with flat earnings — each remaining share represents a slightly larger piece of the company.
FAQ
7 questionsVEEV Investor Questions
Common questions answered from live analyst data and company financials.
01Is Veeva Systems Inc. (VEEV) stock a buy or sell in 2026?
Veeva Systems Inc. (VEEV) is rated Buy by Wall Street analysts as of 2026. Of 43 analysts covering the stock, 29 rate it Buy or Strong Buy, 13 rate it Hold, and 1 rate it Sell or Strong Sell. The consensus 12-month price target is $235, implying +53.5% from the current price of $153. The bear case scenario is $153 and the bull case is $320.
02What is the VEEV stock price target for 2026?
The Wall Street consensus price target for VEEV is $235 based on 43 analyst estimates. The high-end target is $320 (+108.7% from today), and the low-end target is $165 (+7.6%). The base case model target is $243.
03Is Veeva Systems Inc. (VEEV) stock overvalued in 2026?
VEEV trades at 16.9x times forward earnings. The stock trades at a notable premium to the broad market, which is typical for businesses with strong free cash flow and above-average growth expectations. Based on current multiples versus the peer group, the relative model signals expensive versus peers. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
04What are the main risks for Veeva Systems Inc. (VEEV) stock in 2026?
The primary risks for VEEV in 2026 are: (1) Revenue growth slowdown — Revenue growth slowed to 16% year over year in fiscal year 2026, potentially indicating market saturation or competitive pressures. (2) Customer concentration risk — Veeva serves essentially every major pharmaceutical and biotech company, making revenue highly dependent on a concentrated customer base. (3) Guidance uncertainty — Forward-looking statements and guidance are inherently difficult to estimate accurately, creating potential for earnings volatility. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Veeva Systems Inc.'s revenue and earnings forecast?
Analyst consensus estimates VEEV will report consensus revenue of $3.8B (+13.5% year-over-year) and EPS of $7.59 (+33.8% year-over-year) for the upcoming fiscal year. The following year, analysts project $4.2B in revenue.
06When does Veeva Systems Inc. (VEEV) report its next earnings?
A confirmed upcoming earnings date for VEEV is not yet available. Check the Earnings section above for the most recent quarterly report dates and forward estimates.
07How much free cash flow does Veeva Systems Inc. generate?
Veeva Systems Inc. (VEEV) generated $518M in free cash flow over the trailing twelve months — a free cash flow margin of 15.6%. VEEV returns capital to shareholders through and share repurchases ($170M TTM).